United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $539.99, for a total value of $5,129,905.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $175,195,975.57. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Trading Down 1.5%

United Therapeutics stock opened at $533.12 on Friday. The company has a 50-day moving average price of $513.64 and a 200 day moving average price of $540.40. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35. The stock has a market cap of $22.87 billion, a P/E ratio of 19.07, a PEG ratio of 3.87 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter last year, the firm earned $6.41 earnings per share. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, analysts forecast that United Therapeutics Corporation will post 26.40 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of UTHR. Callan Family Office LLC acquired a new position in shares of United Therapeutics during the 2nd quarter valued at about $1,217,000. Andra AP fonden grew its stake in shares of United Therapeutics by 33.5% during the 2nd quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock valued at $18,912,000 after buying an additional 8,760 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of United Therapeutics in the 2nd quarter valued at about $3,359,000. Seven Fleet Capital Management LP purchased a new stake in United Therapeutics during the fourth quarter worth approximately $633,000. Finally, Partners Capital Investment Group LLP purchased a new stake in United Therapeutics during the 2nd quarter worth $1,691,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Royal Bank Of Canada boosted their price objective on United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $728.00 price objective on shares of United Therapeutics in a research note on Wednesday. Finally, Morgan Stanley upped their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $642.69.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics settled six patent and antitrust disputes with Liquidia, reducing legal uncertainty around Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement limits YUTREPIA’s label, including excluding pulmonary hypertension associated with interstitial lung disease, which could help protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
• Positive Sentiment: The settlement is expected to provide United Therapeutics with approximately $380.7 million in payments, while giving investors greater visibility into the competitive landscape for treprostinil therapies. United Therapeutics Stock May Be Undervalued Following the Litigation Settlement
• Positive Sentiment: Traders purchased 12,089 UTHR call options, roughly 220% above average daily volume. The activity signals increased bullish speculation, although options flow does not guarantee sustained buying in the shares.
• Positive Sentiment: Analyst sentiment remains generally favorable. Jefferies reaffirmed a Buy rating with a $728 target, and the broader analyst consensus remains “Moderate Buy,” with targets above recent trading levels.
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her holdings by 2.84%. She still retains a substantial position, so the sale may reflect personal financial planning rather than a change in the company’s outlook. United Therapeutics CEO Stock Sale SEC Filing
• Negative Sentiment: EVP Paul Mahon sold 8,300 shares for approximately $4.52 million, cutting his direct stake by 15.52%. The second executive sale disclosed within two days may weigh on sentiment, even though insider transactions alone do not establish a deterioration in fundamentals. United Therapeutics EVP Stock Sale SEC Filing

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.